Evidence map›Paper›PMID 42256025›Full record

ArticleThe World Allergy Organization journal2026

Knowledge of chronic spontaneous urticaria management among Italian general practitioners: Baseline findings from the BRIDGE study.

Piergiacomo Calzavara-Pinton, Enrico Iemoli, Pallavi Saraswat, Nadine Chapman-Rothe, Ornella Bonavita, Tara Raftery, Vinodh Nallasamy, Mahrukh Zahid, Viviane Sprecher, Abigail Herbst and 4 more

Abstract read
In one paragraph

Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Piergiacomo Calzavara-PintonDermatology Department, University of Brescia, Brescia, Italy.
Enrico IemoliAllergy and Clinical Immunology Unit, ASST FBF-Sacco, Milan, Italy.
Pallavi SaraswatNovartis Healthcare Pvt Ltd, Hyderabad, India.
Nadine Chapman-RotheNovartis Pharma AG, Basel, Switzerland.
Ornella BonavitaNovartis Farma, SpA, Milan, Italy.
Tara RafteryNovartis Ireland Ltd, Dublin, Ireland.
Vinodh NallasamyNovartis Healthcare Pvt Ltd, Hyderabad, India.
Mahrukh ZahidNovartis Pharma AG, Basel, Switzerland.
Viviane SprecherNovartis Pharma AG, Basel, Switzerland.
Abigail HerbstPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Wilmington, NC, USA.
Bridget GaglioPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Wilmington, NC, USA.
Fabio SperanzaPPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK.
Patrick DanielePPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Vancouver, Canada.
Riccardo AseroClinica San Carlo, Ambulatorio di Allergologia, 20037, Paderno Dugnano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with chronic spontaneous urticaria (CSU) often experience diagnostic delays and uncontrolled disease, highlighting the need to improve CSU care. The BRIDGE study, a hybrid type 1 effectiveness-implementation study, evaluated the effectiveness and feasibility of an urticaria care package (UCP) to increase patient-reported outcome (PRO) use in clinical practice and improve CSU care among general practitioners (GPs). Two surveys were conducted, 1 before and 1 after UCP implementation. This report focuses on pre-implementation data regarding the management and knowledge of CSU among GPs in Italy. Methods: Eligible GPs were from Lombardy, an administrative region of Italy, who had been in clinical practice for 3-30 years and had access to electronic medical records. GPs completed a self-administered, web-based survey, prior to UCP implementation. Survey questions included the following topics: awareness and knowledge of CSU, use of CSU-specific PROs or other PROs, attitudes towards UCP adoption, implementation climate, and key factors influencing UCP adoption. The analysis included GPs who completed ≥1 item on the pre-implementation survey. Results: The analysis included 95 GPs (mean age: 37.7 years; female: 50.5%; mean time practicing medicine: 10.1 years). On average over the previous 6 months, GPs managed 3.6 patients with suspected CSU, diagnosed 2.3 patients with CSU, treated 2.1 patients for CSU, and referred 3.0 patients with suspected CSU to a dermatologist or allergist. GPs' primary reasons for referral were seeking confirmation of CSU diagnosis (61.0%), seeking the specialist's opinion (51.2%), and not feeling confident in diagnosing or treating patients with CSU (42.7%). Most GPs had little to no knowledge of CSU (60.0%) or were unaware of the existence of CSU guidelines (61.1%). Among those who were aware of the guidelines, 35.1% applied them on a regular basis. Only 14.7% of GPs reported any use of PROs, and none used PROs with patients with CSU in the past 6 months. Lack of time hindered GPs from discussing PROs with patients all the time (28.6%), most of the time (42.9%), or sometimes (28.6%). Most GPs reported no or limited educational support on evidence-based practices from their clinics, and indicated the importance of further education on CSU diagnosis and management (72.6% important; 7.4% very important) and further training on PRO use (61.1% important; 8.4% very important) for enhancing CSU management. Conclusion: Pre-implementation data revealed substantial knowledge gaps in CSU management among GPs in Lombardy, supporting the need for additional training to improve CSU management.

Indexed as

Chronic spontaneous urticariaCSU managementEffectiveness-implementation studyGeneral practitionersPatient-reported outcomes

Identifiers

PMID42256025
PMCPMC13241996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.